Literature DB >> 2551914

Reversed-phase liquid chromatographic determination of 2',3'-dideoxycytidine in human blood samples.

M Magnani1, L Rossi, M Bianchi, L Cucchiarini, V Stocchi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551914     DOI: 10.1016/s0378-4347(00)82835-2

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  5 in total

1.  A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.

Authors:  F Solimano; G I Bischi; M Bianchi; L Rossi; M Magnani
Journal:  Bull Math Biol       Date:  1990       Impact factor: 1.758

2.  Zalcitabine population pharmacokinetics: application of radioimmunoassay.

Authors:  J M Adams; M J Shelton; R G Hewitt; M DeRemer; R DiFrancesco; T H Grasela; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.

Authors:  D M Burger; H Rosing; C H ten Napel; T Duyts; P L Meenhorst; J W Mulder; C H Koks; A Bult; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 4.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

5.  Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection.

Authors:  M Magnani; A Casabianca; A Fraternale; G Brandi; S Gessani; R Williams; M Giovine; G Damonte; A De Flora; U Benatti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.